Coronary thrombolysis: nonmortality measures of efficacy.
Early reperfusion during AMI results in myocardial salvage, recovery of function and reduced mortality (level I). This can be achieved with all of the currently available thrombolytic agents (level I). Benefits from late reperfusion are not proven but there are data which suggest that delayed reperfusion is better than persistent occlusion (level II). There is now clear evidence that accelerated dose rt-PA (plus heparin) is more effective in reducing mortality than is SK (plus heparin) or a combined regimen of rt-PA/SK (plus heparin) (level I). Soon-to-be published data will refine the extent to which different subgroups benefit and will provide a basis from which to select the most appropriate agent in individual patients. The overall benefit was the reduction of one death per 100 patients treated with rt-PA compared with SK, while the absolute benefit varied considerably among patient subgroups.
Belenkie
I
I
D005069:Evaluation Studies as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D013318:Stroke Volume; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014654:Vascular Patency; D016277:Ventricular Function, Left
D005343:Fibrinolytic Agents; D006493:Heparin